NCT01384253
|
Phase I |
212Pb-TCMC-Trastuzumab + Trastuzumab
|
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy |
Completed |
NCT01625351
|
Phase I |
Fludarabine
Melphalan
Busulfan
Alemtuzumab
|
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas |
Active, not recruiting |
NCT01640665
|
Phase I |
Sorafenib + Capecitabine
|
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors |
Completed |
NCT01916447
|
Phase I |
Bevacizumab
trifluridine/tipiracil hydrochloride
Irinotecan
|
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. |
Completed |
NCT02192541
|
Phase I |
Ganetespib + Aflibercept
|
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas |
Terminated |
NCT02319018
|
Phase I |
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
Alisertib
|
Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors |
Completed |
NCT02344810
|
Phase Ib/II |
AMG 337
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
|
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer |
Withdrawn |
NCT02417753
|
Phase II |
AZD9150
|
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites |
Terminated |
NCT02757391
|
Phase I |
Aldesleukin + Cyclophosphamide + Pembrolizumab
|
T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies |
Not yet recruiting |
NCT03607643
|
Phase Ib/II |
Temozolomide
Bevacizumab + FOLFIRINOX
Bevacizumab + Cannabidiol + FOLFIRINOX
Bortezomib
Bortezomib + Cannabidiol
Cannabidiol + Gemcitabine
Cannabidiol + Temozolomide
Gemcitabine
|
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies |
Not yet recruiting |